The thesis
The news-sentiment strategy runs a simple, intuitive premise: buy names showing positive recent news sentiment and exit when sentiment turns negative. It trades a 24-symbol universe of large-cap US equities spanning tech (AAPL, MSFT, GOOGL, NVDA), financials (JPM, BAC, V, MA), healthcare (JNJ, UNH, PFE, ABBV), and staples/industrials (PG, KO, WMT, XOM, CAT). It is currently flagged live.
Sentiment-driven entry is a reasonable heuristic, but the data suggests the signal is firing far too rarely to draw firm conclusions — and that thinness is the story here.
Backtest and validation
The headline backtest is close to flat: a total return of 0.19% over 451 days, final equity of $10,018.55, a CAGR of roughly 0.10%, and a Sharpe of 0.74. Drawdown was contained at 0.05%, but that is cold comfort when the strategy executed just 2 trades across the entire window with a 0% win rate. Turnover of ~36% and only $2 in fees confirm an almost dormant book.
The walk-forward validation failed. Across four folds, only fold 4 (Dec 2025 – May 2026) produced any activity — 2 trades, a 0.19% return, and a fold Sharpe of 1.5. Folds 1 through 3 recorded zero trades and zero return. That means the entire out-of-sample result rests on a single active window, so foldsPositive stands at 1 of 4.
The statistics are genuinely mixed. The Probabilistic Sharpe Ratio (PSR) of 0.923 looks strong, but the Deflated Sharpe Ratio (DSR) of 0.551 — which accounts for the 6 trials run — is far more sober. With performance concentrated in one fold, the honest read is that we have almost no independent evidence the edge generalises.
Recent live activity
The live paper account tells the same low-activity story. The last executed trades were a cluster of buys in late May through early July 2026 — AAPL, MSFT, BAC, UNH, and GOOGL. Since then, every scheduled run from 17 – 24 August has executed nothing, logging one or two rejections per run. Cash has sat frozen at $990.06 while total account value drifted between roughly $10,227 and $10,335, largely tracking existing holdings rather than new signals.
The verdict
Strengths: the drawdown profile is tight, fees are negligible, and when the strategy does trade (fold 4) it posted a respectable fold Sharpe. The thesis is transparent and easy to reason about.
Risks: the sample is dangerously small. Two backtest trades, a 0% win rate, three empty validation folds, and a week of live rejections point to a signal that either sets an entry bar it rarely clears or is being blocked at execution. A validation status of failed should be taken at face value — the DSR undercuts the flattering PSR, and one positive fold is not a track record.
Our recommendation is patience with scrutiny: keep news-sentiment live only in paper, investigate why recent runs are rejecting orders, and revisit once the strategy has accumulated enough trades to say anything statistically meaningful.